ZUG, Switzerland, May 3 /PRNewswire-FirstCall/ -- Biogen Idec
(Nasdaq: BIIB) today announced that the Israeli Ministry of Health has
approved AMEVIVE(R) (alefacept) for sale in Israel for treatment of adult
patients with moderate-to-severe chronic plaque psoriasis who are candidates
for systemic therapy or phototherapy. Medison Pharma Ltd. of Petach Tikvah is
the AMEVIVE distributor in Israel.
(Logo: http://www.newscom.com/cgi-bin/prnh/20031112/LAW121LOGO )
In addition, the company said it has received a positive opinion letter
from Swissmedic, the regulatory authority in Switzerland, and is in the final
stages of negotiating indication and securing market approval.
AMEVIVE was approved last year in the United States. Applications for
marketing authorization have also been submitted in Australia and Canada.
Biogen Idec creates new standards of care in oncology and immunology. As
a global leader in the development, manufacturing and commercialization of
novel therapies, Biogen Idec transforms scientific discoveries into advances
in human healthcare. For press releases and additional information about the
company, please visit http://www.biogenidec.com.
Media Contact:
Jose Juves
Associate Director, Public Affairs
Biogen Idec
(617) 914-6524
Investment Community Contact:
Christina Dillon
Manager, Investor Relations
Biogen Idec
(617) 679-2812
SOURCE Biogen Idec
 back to top
Related links:
http://www.biogenidec.com
Company News On-Call:
http://www.prnewswire.com/comp/101550.html
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20031112/LAW121LOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
CONTACT:
Jose Juves, Associate Director, Public
Affairs, +1-617-914-6524, or Investment Community Contact,
Christina Dillon, Manager, Investor Relations, +1-617-679-2812,
both of Biogen Idec
|
